LTR Pharma (ASX:LTP) said the first patient-specific prescriptions for ROXUS, its intranasal medication for erectile dysfunction support, received through Shed's men's health telehealth platform Mavrox, have been fulfilled in the US, according to a Tuesday Australian bourse filing.

Strive Pharmacy set up the operational systems required to receive, compound and fulfil valid patient-specific ROXUS prescriptions.

Its shares climbed 1% in recent trading on Tuesday.